Pamalican Asset Management Ltd Purchases New Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Pamalican Asset Management Ltd acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 25,000 shares of the company’s stock, valued at approximately $1,338,000.

Other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Janux Therapeutics by 27.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after acquiring an additional 6,547 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after acquiring an additional 721,563 shares in the last quarter. Polar Asset Management Partners Inc. bought a new stake in shares of Janux Therapeutics in the 3rd quarter worth about $613,000. Finally, Point72 Asset Management L.P. raised its stake in shares of Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Janux Therapeutics

In related news, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,668 shares of company stock worth $548,183. 29.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush restated an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $92.44.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $26.99 on Friday. The firm has a market capitalization of $1.60 billion, a PE ratio of -23.07 and a beta of 3.23. Janux Therapeutics, Inc. has a 1-year low of $25.77 and a 1-year high of $71.71. The business’s fifty day moving average price is $34.46 and its two-hundred day moving average price is $45.46.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.